This month Anthropic and OpenAI each disclosed evidence that leading Chinese AI labs have illicitly used American models to ...

Among the several Se7en dupes released in the 1990s, The Bone Collector is heading to a new streaming platform. Find out more.

Are your loved ones in luck this year? Seeour predictions for all the zodiac signs in the Year of the Horse. If your Chinese zodiac forecast warns of challenges in the coming year, or if you want to ...

On a wet and miserable January afternoon in west London, Feng is sheltering in front of a TV blasting Stranger Things. Dressed in a pair of grey joggers, offset by bright yellow socks, he looks out of ...

Wegovy and Ozempic maker Novo Nordisk NOVO.B-16.48%decrease; red down pointing triangle filed a lawsuit against Hims & Hers as it seeks a ban on the telehealth provider offering copycat versions of ...

Feb. 9 (UPI) --Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday. Novo Nordisk claims that Hims & ...

Add Yahoo as a preferred source to see more of our stories on Google. Feng shui master Joey Yap was in Singapore, hosting two events at Resorts World Sentosa — Feng Shui & Astrology 2026 on Jan 31, ...

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss ...

Injection pens for Wegovy and Ozempic at a Novo Nordisk plant. - Carsten Snejbjerg/Bloomberg News Wegovy and Ozempic maker Novo Nordisk filed a lawsuit against Hims & Hers as it seeks a ban on the ...

Hims & Hers scrapped plans Saturday to sell a $49 knockoff of Novo Nordisk’s Wegovy weight-loss pill, one day after the online telehealth company was threatened with legal action by the U.S. Food and ...

Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened ...

FDA leadership indicated planned swift enforcement against companies mass-marketing non-approved “copycat” drugs, underscoring inability to verify safety, quality, or effectiveness outside the ...